 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking data from the Companys Phase 2 REDUX trial of DM199 in chronic kidney disease CKD will be presented at the American Society of Nephrologys ASN annual Kidney Week meeting. The abstract will include an update to the Phase 2 REDUX interim data the Company a 